Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$5.56 USD
-0.55 (-9.00%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $5.59 +0.03 (0.54%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Brokerage Reports
Emergent Biosolutions Inc. [EBS]
Reports for Purchase
Showing records 181 - 200 ( 237 total )
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
EBS Reported Better-Than-Expected Q3 Financials - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q2:13 Update - Strong BioThrax Revenues - Bracco Acquisition Closed - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Aug. 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q2:13 Earnings Preview: Strong BioThrax Revenue Uptick Expected - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q1:13 Update - Light Q1, as Anticipated - Guidance Reaffirmed
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q1:13 EPS Preview, Unlikely to Be a Surprise with Recently Affirmed Guidance, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Audited Q4:12 Financial Results And Re-Affirmed 2013 Income Guidance Of $20-30M - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
TB Vaccine Failure a Negative for the Pipeline, but a Financial Positive, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
BioThrax Revenues and EPS in Line with our Estimates - 3-Year Growth Plan Announced - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G